Novel Immunotherapy Combos Show Promise in Stage III Non-Small Cell Lung Cancer
Adding oleclumab or monalizumab to consolidation with durvalumab can improve clinical outcomes in patients with unresectable stage III non-small cell lung cancer (NSCLC), a phase 2 trial suggests. Combining durvalumab with oleclumab or monalizumab produced…